相似文献
1
Are current development programs realising the full potential of new agents?
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S23. doi: 10.1186/bcr2752.
2
New research on the treatment of small HER2-positive breast cancers.
Clin Adv Hematol Oncol. 2014 Feb;12(2):124-7.
3
Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.
Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90.
4
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.
J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038.
5
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?
Breast Cancer. 2012 Jul;19(3):212-7. doi: 10.1007/s12282-011-0277-2. Epub 2011 Jun 1.
6
[Novel target therapies used in breast cancer management].
Vopr Onkol. 2011;57(5):592-600.
7
Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.
Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
8
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501.
9
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Med Res Rev. 2012 Jan;32(1):166-215. doi: 10.1002/med.20209. Epub 2010 Oct 25.
10
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18.
本文引用的文献
1
Molecular basis for therapy resistance.
Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24.
2
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).
Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13.
3
Complex landscapes of somatic rearrangement in human breast cancer genomes.
Nature. 2009 Dec 24;462(7276):1005-10. doi: 10.1038/nature08645.
4
Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.
J Clin Oncol. 2010 Jan 20;28(3):361-3. doi: 10.1200/JCO.2009.24.0838. Epub 2009 Dec 14.
5
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.
6
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.
7
The cancer genome.
Nature. 2009 Apr 9;458(7239):719-24. doi: 10.1038/nature07943.
8
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.
Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.
9
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.
10
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.
J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9.
Zotero 插件